Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Key Points

• Short interest in Invivyd, Inc. increased by 72.8% in August, rising to 5.27 million shares.
• Analysts have mixed perspectives, with D. Boral Capital lowering their target price from $3.00 to $1.00 while HC Wainwright maintains a "buy" rating with a $5.00 target.
• Invivyd shares experienced a 10.5% decrease in trading, reaching $1.28, following disappointing earnings results that missed revenue estimates by over $11 million.

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) was the recipient of a significant increase in short interest in August. As of August 31st, there was short interest totaling 5,270,000 shares, an increase of 72.8% from the August 15th total of 3,050,000 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average trading volume of 5,130,000 shares, the days-to-cover ratio is currently 1.0 days. Based on an average trading volume of 5,130,000 shares, the days-to-cover ratio is currently 1.0 days. Currently, 4.2% of the shares of the stock are short sold.

Insider Buying and Selling

In other news, insider Jill Andersen sold 49,402 shares of the business's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $0.57, for a total transaction of $28,159.14. Following the sale, the insider directly owned 84,446 shares in the company, valued at approximately $48,134.22. The trade was a 36.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 277,654 shares of company stock worth $167,215 over the last three months. 25.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Invivyd

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Advisers LP boosted its holdings in shares of Invivyd by 1,276.5% during the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company's stock worth $135,000 after buying an additional 282,100 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Invivyd by 35.2% during the 4th quarter. Deutsche Bank AG now owns 874,406 shares of the company's stock worth $385,000 after buying an additional 227,463 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company's stock worth $163,000 after buying an additional 204,188 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after buying an additional 87,358 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Invivyd during the 1st quarter worth approximately $66,000. 70.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on IVVD shares. D. Boral Capital reduced their price target on Invivyd from $3.00 to $1.00 and set a "buy" rating on the stock in a report on Monday, August 25th. HC Wainwright restated a "buy" rating and set a $5.00 price target on shares of Invivyd in a report on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $3.18.

Invivyd Trading Down 2.4%

IVVD stock traded down $0.03 during trading on Friday, hitting $1.22. The company had a trading volume of 1,859,348 shares, compared to its average volume of 14,877,766. The business has a 50-day moving average of $0.88 and a 200-day moving average of $0.77. Invivyd has a one year low of $0.35 and a one year high of $2.74. The stock has a market cap of $146.57 million, a PE ratio of -1.33 and a beta of 0.55.

Invivyd (NASDAQ:IVVD - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). Invivyd had a negative net margin of 238.33% and a negative return on equity of 177.89%. The company had revenue of $11.79 million during the quarter, compared to the consensus estimate of $23.16 million. Research analysts forecast that Invivyd will post -1.64 EPS for the current year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.